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2154while platelet aggregation returned to baseline after
7 to 8 weeks (5). We also demonstrated a progressive
reduction in platelet sensitivity to aspirin in long-
term aspirin-treated patients.
The genomic response to a pharmacological “chal-
lenge” with aspirin has also been demonstrated. After
aspirin administration, a set of platelet-enriched
genes and proteins associated with platelet function
and cardiovascular complications have been identi-
ﬁed. Moreover, increased platelet expression of
glycoprotein IIIa with aspirin treatment has been
demonstrated.
In conclusion, we suggest a better deﬁnition of the
impact of prior aspirin use, because the capability of
aspirin in changing protein platelet expression may
be useful to better understand high on-aspirin treat-
ment platelet reactivity.*Fabio M. Pulcinelli, MD
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REPLY: Aspirin Treatment and OutcomesAfter Percutaneous Coronary Intervention
Results of the ISAR-ASPI RegistryWe thank Dr. Pulcinelli and colleagues for their in-
terest in our publication (1). The high proportion of
patients (>90%) presenting on aspirin therapy in our
cohort likely would not enable a reliable analysis of
the role of the presence or absence of this therapy on
the platelet response to aspirin as measured in this
study.However, the fact that a signiﬁcantly lower pro-
portion of patients taking aspirin showed high on-
aspirin platelet reactivity (91.2% in patients with
vs. 93.8% in those without high on-aspirin platelet
reactivity; p ¼ 0.0006) does not support the authors’
hypothesis. In addition, as mentioned in the results
section of our paper (1), prior aspirin therapy was also
included in the multivariate model for the primary
outcome, the composite of death or stent thrombosis
at 1 year. From this model, prior aspirin therapy
was associated with an adjusted hazard ratio of 0.66
(95% conﬁdence interval: 0.45 to 0.96; p ¼ 0.03) for
the occurrence of the primary outcome, suggesting a
protective role against ischemic events.*Katharina Mayer, MD
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Coll Cardiol 2014;64:863–71.Does Size Matter?In Search of a Physiological Deﬁnition of
Myocardial AtrophyMechanical unloading using left ventricular assist
devices (LVADs) induces reverse remodeling of the
failing myocardium to levels that are possibly supe-
rior to any other strategy. However, evidence of a
